Charting the Course of Liquid Biopsy in Precision Prevention and Treatment

Meeting Date and Time
Virtual via WebEx
NCI Division of Cancer Prevention

Date Posted


Day #1: Wednesday, December 15 “Charting the Course!”

Moderator: Fred Hochberg, M.D., Consultant, Mass General Hospital
11:00 a.m. – 11:05 a.m. Welcome
Lynn Sorbara, Ph.D.
Program Director, Cancer Biomarkers Research Group (CBRG) NCI/DCP
11:05 a.m. – 11:20 a.m. Introduction and Charge
Sudhir Srivastava, M.P.H., Ph.D.
Chief of CBRG, NCI/DCP
Moderator: Richard Cote, M.D., Washington University
11:20 a.m. – 11:50 a.m. "ctDNA: From Past Success to Clinical Integration"
  • Review the areas in which ctDNA provides useful or emerging clinical information.
  • Discuss the physiologic and technical challenges for different scenarios.
  • Identify the key challenges in the most promising areas for clinical implementation.
David Sidransky, M.D.
Professor of Oncology, Director of Head and Neck Cancer, Johns Hopkins Medicine
11:50 a.m. – 11:55 a.m. Q/A
11:55a.m. – 12:25 p.m. “The Arena of Liquid Biopsy”
Mark Watson, M.D., Ph.D.
Associate Professor of Pathology and Immunology, Washington University School of Medicine
12:25 p.m. – 12:30 p.m. Q/A
12:30 p.m. – 1:00 p.m. “Personalized Medicine Initiatives and The Role of Novel Analytics”
Razelle Kurzrock, M.D.
Chief Medical Advisor and Co-founder, CureMatch
1:00 p.m. – 1:05 p.m. Q/A
1:05 p.m. – 1:15 p.m. Break
Moderator: Nickolas Papadopoulos, Ph.D., Johns Hopkins University
1:15 p.m. – 1:45 p.m. “Clinical Applications of Multi-analyte Analyses for Liquid Biopsy”
Luis Diaz, M.D.
Chief of Solid Tumor Oncology, Memorial Sloan Kettering
1:45 p.m. – 1:50 p.m. Q/A
1:50 p.m. – 2:20 p.m. “Circulating Tumor Cells: A Critical Analyte for Cancer Research and Management”
Richard Schlegel, M.D., Ph.D.
Chair of Pathology, Georgetown University
2:20 p.m. – 2:25 p.m. Q/A
2:25 p.m. – 2:55 p.m. “Cancer Early Detection, Classification and Monitoring using Plasma Cell-Free Methylomes”
Daniel De Carvalho, Ph.D.
Associate Professor, University of Toronto
2:55 p.m. – 3:00 p.m. Q/A
3:00 p.m. – 3:45 p.m. NCI Liquid Biopsy Consortium Forum
Moderators: David Wong, D.M.D.
University of California, Los Angeles
Bob Carter, M.D.
Massachusetts General Hospital
Participation by all Consortium Members

Day #2: Thursday, December 16 “Looking Ahead!”

11:00 a.m. – 11:10 a.m. Recap of Day #1 and Path Forward
Sudhir Srivastava, M.P.H., Ph.D.
Chief of CBRG, NCI/DCP
Lynn Sorbara, Ph.D.
Program Director, CBRG, NCI/DCP
11:10 a.m. – 11:30 a.m. “NCI Vision for Liquid Biopsy”
Philip Castle, Ph.D., M.P.H.
Director, Division of Cancer Prevention, NCI
11:30 a.m. – 11:35 a.m. Q/A
Moderator: Hakho Lee, Ph.D., Massachusetts General Hospital
11:35 a.m. – 12:05 p.m. "Multi-Modal Data Integration for Fluid Biomarkers in Cancer"
  • How fluid biomarkers can work in the context of multi-modal non-invasive data.
  • Focus on germline and radiologic information.
  • Touch upon incorporation of primary tumor data and multiple types of fluid analytes into unified biomarkers using systems biology and machine-learning strategies.
Paul Boutros, Ph.D., M.B.A.
Professor of Human Genetics, University of California, Los Angeles
12:05 p.m. – 12:10 Q/A
12:10 p.m. – 12:40 p.m. Title: TBA
Sean Khozin, M.D., M.P.H.
Chief Executive Officer of CancerLinQ LLC
12:40 p.m. – 12:45 p.m. Q/A
12:45 p.m. – 1:15 p.m. Title: TBA
Puneet Souda, M.B.A.
Managing Director, Life Science Tools and Diagnostics, SVB Leerink
1:15 p.m. – 1:20 p.m. Q/A
1:20 p.m. - 1:30 p.m. Break
Moderator: Abhijit Patel, M.D., Yale University
1:30 p.m. – 2:00 p.m. “Risk Benefit Analyses for Liquid Biopsy Studies”
John Schneider, Ph.D.
Chief Executive Officer and Founder of Avalon
2:00 p.m. – 2:05 p.m. Q/A
2:05 p.m. – 2:35 p.m. “Novel Approaches to Circulating Tumor Cell Analyses”
Daniel Adams, B.S.
Head Research Scientist, Director of Clinical R & D, Creatv MicroTech, Inc.
2:35 p.m. – 2:40 p.m. Q/A
2:40 p.m. – 3:10 p.m. “Finding the Needle in the Haystack!”
  • Detecting mutant-ctDNA in a sea of healthy-cfDNA is the central, technical challenge to early cancer detection—finding the needle in the haystack.
  • Liquid biopsy companies are solving it by blurring the lines between DNA sequencing and computational biology.
Michele Canzi, M.B.A.
Stealth Biotech Company
3:10 p.m. – 3:15 p.m. Q/A
3:15 p.m. – 3:45 p.m. Wrap Up

Points of Contact

Lynn Sorbara, Ph.D.

Juan Villanueva